Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial)
Douglas Hinerfeld, A. Thompson(Jacksonville College), Saranya Chumsri(Jacksonville College), Henrik Lindman(Uppsala University), Heather Ann Brauer(Gates Foundation), Jennifer M. Kachergus(Norwegian University of Science and Technology), Karama Asleh(University of British Columbia), Heikki Joensuu(Orion Corporation (Finland)), Torsten O. Nielsen(University of British Columbia), Susanna Lauttia(University of Helsinki)
Cited by 0
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k